Discovery of a highly potent and orally available importin-<i>β</i>1 inhibitor that overcomes enzalutamide-resistance in advanced prostate cancer.
Journal Information
Full Title: Acta Pharm Sin B
Abbreviation: Acta Pharm Sin B
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Pharmacology & Pharmacy
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflicts of interest The authors declare no conflicts of interest."
"This work was supported by the Natural Science Foundation of China (Nos. 82273804, 81973195, 81872891, and 81973203), the Southern Marine Science and Engineering Guangdong Laboratory (Zhuhai) (No. SML2021SP301, China), Open Program of Shenzhen Bay Laboratory (No. SZBL2021080601007, China), the Guangdong Natural Science Funds for Distinguished Young Scholar (No. 2019B151502016, China), Guangdong-Hong Kong-Macao research team project of the Guangdong Basic and Applied Basic Research Foundation (No. 2022B1515130008, China)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025